Will WATCHMAN Sales Aid Boston Scientific''s Q2 Earnings?
Boston Scientific Corporation (NYSE: BSX ) is scheduled to report second-quarter 2024 results on Jul 24, before the opening bell. In the last reported quarter, the company''s earnings per share of 56 cents exceeded the Zacks Consensus Estimate by 9.8%. BSX''s bottom line beat estimates in each of the trailing four quarters. The company delivered a trailing four-quarter earnings surprise of 7.49%, on average. Q2 Estimates The Zacks Consensus Estimate for second-quarter total revenues is pegged at $4.02 billion, suggesting an improvement of 11.7% from the prior-year quarter''s reported number. The consensus mark for adjusted earnings stands at 58 cents per share, implying a 9.4% rise from the year-ago quarter''s reported figure. For the second quarter of 2024, the company projected revenue growth in the range of approximately 10.5-12.5% on a reported basis (an increase of 10-12% organically). Adjusted earnings are expected in the range of 57-59 cents per share. Estimate Revision Trend Ahead of Earnings The Zacks Consensus Estimate for Boston Scientific''s second-quarter earnings has remained unchanged at 58 cents per share in the past 60 days.
https://www.benzinga.com/general/biotech/24/07/39799910/will-watchman-sales-aid-boston-scientifics-q2-earnings